J&J’s recent recall of Motrin and other pharmaceutical products is more than a cautionary tale in crisis management. It raises a very important question: Why do companies hesitate to address known risks (in this case the QC problems at a specific manufacturing facility)? As Douglas McIntyre, editor of 24/7 Wall Street, stated in a recent posting, “Acting early would probably be harmless at worst and might be critical to success.” However, he admits that few companies have gotten the message. But why?…